RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI - News) (http://www.biodeliverysciences.com) today announced that the clinical development program for its lead product, BEMATM Fentanyl, will be expanded to assess the efficacy and safety of the product for the treatment of breakthrough pain associated with other chronic pain conditions beyond cancer. This expanded program is funded by and coordinated with Meda AB, BDSI’s U.S. and European commercial partner for BEMATM Fentanyl.
